Yamamoto, Noboru
Nokihara, Hiroshi
Yamada, Yasuhide
Shibata, Takashi
Tamura, Yosuke
Seki, Yoshitaka
Honda, Kazunori
Tanabe, Yuko
Wakui, Hiroshi
Tamura, Tomohide
Funding for this research was provided by:
ONO Pharmaceutical Co., Ltd.
Bristol-Myers Squibb company
Article History
Received: 29 August 2016
Accepted: 18 November 2016
First Online: 8 December 2016
Compliance with ethical standards
:
: All authors received research funding from Ono Pharmaceuticals and Bristol-Myers Squibb for conducting the study and preparing this report. Other disclosures are as follows. Noboru Yamamoto: personal fees from AstraZeneca, Chugai, Eli Lilly, Novartis and Pfizer, and grants from Astellas, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa-Hakko Kirin, Novartis, Pfizer, Quintiles, Taiho Pharmaceutical and Takeda. Hiroshi Nokihara: personal fees from Taiho Pharmaceutical and grants from Merck-Serono, Pfizer and Taiho Pharmaceutical; Yasuhide Yamada: personal fees from Chugai, Taiho Pharmaceutical, and Yakult, and grants from Astra-Zeneca, Daiichi-Sankyo, Merck-Serono, and Novartis; Yoshitaka Seki: personal fees from Pfizer, AstraZeneca, Boehringer Ingelheim, and Chugai, and a Health Labour Sciences research grant; Tomohide Tamura: personal fees from AstraZeneca, Astellas, Ono Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly, Kyowa-Hakko Kirin, Novartis, Merck-Serono, Pfizer, Sanofi, Taiho Pharmaceutical, and Yakult. Kazunori Honda, Takashi Shibata, Yosuke Tamura, Yuko Tanabe, Hiroshi Wakui: nothing additional to disclose.
: The study was approved by the institutional review board of the National Cancer Center, Tokyo, Japan. The study was conducted in compliance with the ethical principles originating in the Declaration of Helsinki.
: Written informed consent was obtained from all individual patients included in the study.
: This study was funded by Ono Pharmaceutical Co., Ltd. and Bristol-Myers Squibb.